STOCK TITAN

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

CRISPR Therapeutics (Nasdaq: CRSP) announced participation in two virtual investor conferences. The Truist Securities Life Sciences Summit is set for May 5, 2021, at 11:20 a.m. ET. Following that, the 2021 Bank of America Healthcare Conference will occur on May 12, 2021, at 2:00 p.m. ET. Live webcasts will be available on the company's website, with replays archived for 14 days post-presentation. CRISPR Therapeutics focuses on gene-based medicines, leveraging its proprietary CRISPR/Cas9 technology across various disease areas.

Positive
  • None.
Negative
  • None.

ZUG, Switzerland and CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the following virtual investor conferences in May:

Truist Securities Life Sciences Summit
Date: Wednesday, May 5, 2021
Time: 11:20 a.m. ET

2021 Bank of America Healthcare Conference
Date: Wednesday, May 12, 2021
Time: 2:00 p.m. ET

A live webcast of these events will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcasts will be archived on the Company's website for 14 days following each presentation.

About CRISPR Therapeutics
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

CRISPR THERAPEUTICS® word mark and design logo are trademarks and registered trademarks of CRISPR Therapeutics AG. All other trademarks and registered trademarks are the property of their respective owners.

Investor Contact:
Susan Kim
+1-617-307-7503
susan.kim@crisprtx.com

Media Contact:
Jennifer Paganelli
Real Chemistry on behalf of CRISPR
+1-347-658-8290
jpaganelli@realchemistry.com


FAQ

What is the schedule for the CRISPR Therapeutics investor conferences in May 2021?

CRISPR Therapeutics will participate in two conferences: the Truist Securities Life Sciences Summit on May 5, 2021, at 11:20 a.m. ET, and the 2021 Bank of America Healthcare Conference on May 12, 2021, at 2:00 p.m. ET.

How can I watch the CRISPR Therapeutics investor conference presentations?

Live webcasts of the CRISPR Therapeutics investor conferences will be available on the 'Events & Presentations' page in the Investors section of the company's website.

What technology does CRISPR Therapeutics use for gene editing?

CRISPR Therapeutics utilizes the CRISPR/Cas9 gene editing technology to develop transformative gene-based medicines for serious diseases.

What areas of disease does CRISPR Therapeutics focus on?

CRISPR Therapeutics has a portfolio of therapeutic programs across various disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases.

Where is CRISPR Therapeutics headquartered?

CRISPR Therapeutics is headquartered in Zug, Switzerland, with R&D operations based in Cambridge, Massachusetts.

CRISPR Therapeutics AG

NASDAQ:CRSP

CRSP Rankings

CRSP Latest News

CRSP Stock Data

4.05B
83.89M
1.71%
72.21%
21.78%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
ZUG